

**From:** Maruna, Thomas  
**Sent:** Monday, November 30, 2015 11:34 AM  
**To:** 'Denloye, Aderonke O'  
**Subject:** November 30. 2015 Information Request - BLA 125596.0 - Please Respond by December 12. 2015

**Importance:** High

Baxalta US Inc.  
Attention: Ms. Aderonke Denloye  
November 30, 2015  
Sent by email

Dear Ms. Denloye:

We are reviewing your September 14, 2015 biologics license application (BLA) to treat primary immune deficiency disorders associated with defects in humoral immunity for the following:

<b>STN</b>	<b>Name of Biological Products</b>
125596/0	Immune Globulin Subcutaneous (Human), 20% Solution

We have reviewed your analytical procedures and validation of analytical procedures for “(b) (4) of Gammagard S/D, Gammagard Liquid/Kiovig and IGSV 20% Product by (b) (4)” and we have following information request:

1. Method (Doc ID: LE-13-A04001-CTP00)
  - Please confirm that no (b) (4) is used for the IGSC 20% sample before (b) (4) in section 4.2
  - Please specify the (b) (4) method for (b) (4) in section 5
  - Please specify the (b) (4) during the (b) (4)
  - Please provide details of (b) (4) in section 3.4
2. Validation (Doc ID: LE-65-A04001S/01 and PV-LA-09.007)

The (b) (4) is identified as a compendial method ((b) (4)) in the submission. In your validation report, only the precision is evaluated. The (b) (4) assay is a critical assay directly related to the safety of this product. Therefore, a full validation of the method is necessary, which means it should be validated as a quantitative method for the (b) (4) and as a quantitative impurity test for the (b) (4) as well as for the (b) (4) and address necessary validation characteristics, including specificity, linearity, precision, accuracy, and for the impurities also LOQ.

Please submit your responses to question 1 as an amendment to this file by December 12, 2015 referencing the date of this request; please provide a timeline for question 2.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

The action due date for these files is September 13, 2016.

If you have any questions, please contact me.

Very Respectfully,

Thomas J. Maruna, MSc, MLS(ASCP)<sup>CM</sup>

Lieutenant, U.S. Public Health Service

Senior Regulatory Management Officer

Food and Drug Administration

Center for Biologics Evaluation and Research

Office of Blood Research and Review

10903 New Hampshire Ave.

Silver Spring, MD 20993

[thomas.maruna@fda.hhs.gov](mailto:thomas.maruna@fda.hhs.gov)

O: (240) 402-8454

[www.usphs.gov](http://www.usphs.gov)



"THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.